MARCO and neoplasm: As the treatment scheme depicted in Figure7A, we administered isotype mAbs, anti‐MARCO, anti‐PD‐1, or a combination of anti‐MARCO and anti‐PD‐1 mAbs to orthotopic Renca tumor‐bearing mice, followed by In Vivo Imaging Systems (IVIS) to evaluate the therapeutic effects on the tumor growth.